Introducing restriction factors into the genome of an AIDS virus host species

将限制因子引入艾滋病病毒宿主物种的基因组中

• 批准号: 9025396
• 负责人: Eric M. Poeschla
• 金额: $ 68.7万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-03-02 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9025396
• 关键词: AIDS prevention; AIDS therapy; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Alleles; Animal Model; Animals; Antiviral Agents; Basic Science; Biology; Breeding; Cell Lineage; Cells; Cultured Cells; Data; Development; Disease; Disease model; Engineering; Evolution; Family Felidae; Feline Acquired Immunodeficiency Syndrome; Feline Immunodeficiency Virus; Felis catus; Functional disorder; Funding; Future; Fv-1 protein; Gene Transfer Techniques; Genes; Genetic; Genetic Structures; Genome; Germ Cells; Goals; Grant; HIV; HIV-1; Homo sapiens; Host Defense; Human; Immune; Immunity; Infection; Injection of therapeutic agent; Intravenous; Knowledge; Laboratories; Lymphocyte; Lymphoid; Macaca; Mediating; Methods; Modeling; Modification; Mosaicism; Mus; Mutation; Natural Immunity; Natural Selections; Nature; Organ; Oryctolagus cuniculus; Outcome; Pattern; Pilot Projects; Predisposition; Primate Lentiviruses; Primates; Process; Proteins; Publishing; Rattus; Research; Research Personnel; Retroviridae; Rodent; Science; Signal Transduction; Subfamily lentivirinae; System; TRIM Motif; Testing; Therapeutic; Time; Tissues; Transgenic Organisms; Variant; Viral; Viremia; Virus; Whole Organism; Work; adaptive immunity; base; experience; gene therapy; genetic manipulation; in vivo; innovation; interest; model development; novel; nuclear transfer; offspring; pandemic disease; research study; response; small molecule; success; transmission process; vector; vif Genes

DESCRIPTION (provided by applicant): Species-specific restriction factors have attracted exceptional research interest from HIV/AIDS researchers. This kind of innate immunity is mediated by proteins such as APOBEC3 proteins, TRIM5alpha, TRIMCyp, and BST2/Tetherin. To infect new species, retroviruses must evolve specific countermeasures. Remarkably, it is now believed that the accessory genes (vif, vpx, vpu, nef, and probably vpr) of primate lentiviruses are largely devoted to countering the antiviral effects of species-specific restrictio factors. There is intensive interest in therapeutic application of restriction factor science via gne therapy or small molecule approaches. Much remains unknown about how these factors actually function in vivo, in a body. This includes whether they can be exploited to protect against trans-mucosal or percutaneous infection. The idea is compelling because these factors can act immediately, before signaling cascades and/or adaptive immunity are mounted, and in a cell-autonomous way. The experiments in this field have largely been conducted in cultured cells of diverse species, with great success. There are also limited observations of allelic influences in macaques and humans (and, previously, the Fv1 system for mouse retroviruses). However, controlled body-level genetic manipulation of a susceptible species has not been possible for lentiviruses. We do not know how much a single restriction factor or a combination of them can defend a host and at which of three broadly considered levels: initial infection, development of systemic viremia, and disease (AIDS). Restriction factors have never been experimentally tested by introduction into the germline of a species susceptible to a lentivirus. Here we will carry out such experiments for the first time. We will do this in a natural lentiviral host that develops AIDS and is afflicted with a pandemic AIDS virus. We enabled efficient cat transgenesis to make this possible. We include the results of this pilot project as preliminary data for this R01 proposal. Unlike rodents, the domestic cat is naturally susceptible to an AIDS virus. Moreover, FIV is restricted by primate restriction factors, including both Old and New World TRIMCyps. This is an ideal use of this AIDS model. It will enable experiments that cannot be done in mice, rats, rabbits, macaques or people. We will determine the ability of restriction factor(s) to block FIV at the three potential levels described above. We will answer whether a species can be rendered genetically immune to its AIDS virus by addition of restriction factor genes. We will also determine whether and how the virus evolves in response. We will determine, in turn, if protected cell lineages are selected and enriched in vivo as the virus replicates. Thus, this project is innovative at the basic science level and the translational level We believe we are an ideal lab to do this because we have years of experience working with the cat and analyzing its tissues, we have specific experience with FIV and HIV, we have background and knowledge in host cell factors and restriction, and we enabled efficient feline transgenesis.

描述（由申请人提供）：种属特异性限制因子吸引了艾滋病毒/艾滋病研究人员的特殊研究兴趣。这种先天免疫由APOBEC 3蛋白、TRIM 5 α、TRIMCyp和BST 2/Tetherin等蛋白质介导。为了感染新的物种，逆转录病毒必须进化出特定的对策。值得注意的是，现在认为灵长类慢病毒的辅助基因（vif，vpx，vpu，nef，可能还有vpr）主要致力于对抗物种特异性限制因子的抗病毒作用。限制因子科学通过基因治疗或小分子方法的治疗应用引起了人们的浓厚兴趣。 关于这些因子在体内，在身体中实际上是如何起作用的，还有很多未知之处。这包括它们是否可以用于防止经粘膜或经皮感染。这个想法是令人信服的，因为这些因素可以立即发挥作用，在信号级联和/或适应性免疫安装之前，并以细胞自主的方式。这一领域的实验主要在不同物种的培养细胞中进行，并取得了巨大成功。在猕猴和人类中也有有限的等位基因影响的观察（以及以前的小鼠逆转录病毒的Fv 1系统）。然而，对于慢病毒，易感种属的受控体水平遗传操作是不可能的。我们不知道一个单一的限制因子或它们的组合能在多大程度上保护宿主，也不知道在三个广泛考虑的水平中的哪一个：初始感染、系统性病毒血症的发展和疾病（艾滋病）。限制因子从未通过引入对慢病毒敏感的物种的种系进行实验测试。在这里，我们将首次进行这样的实验。我们将在一个天然的慢病毒 感染艾滋病病毒的宿主。 我们使高效的猫转基因成为可能。我们将该试点项目的结果作为R 01提案的初步数据。与啮齿类动物不同，家猫天生容易感染艾滋病病毒。此外，FIV受到灵长类限制因子的限制，包括旧世界和新世界TRIMCyps。这是一个理想的使用这种艾滋病模型。它将使实验，不能在小鼠，大鼠，兔子，猕猴或人。我们将确定限制因子在上述三个潜在水平阻断FIV的能力。我们将回答一个物种是否可以通过增加限制因子基因而对艾滋病病毒产生遗传免疫。我们还将确定病毒是否以及如何进化。我们将依次确定，当病毒复制时，是否选择受保护的细胞谱系并在体内富集。因此，这个项目在基础科学水平和转化水平上都是创新的。我们相信我们是做这件事的理想实验室，因为我们有多年与猫合作和分析其组织的经验，我们有FIV和HIV的具体经验，我们有宿主细胞因子和限制的背景和知识，我们实现了高效的猫科动物转基因。